Monatepil
Monatepil (AJ-2615 free base) is a calcium antagonist with potent α1-adrenoceptor blocking activity. Monatepil inhibits vasopressin- or methacholine-induced ischemic electrocardiographic changes in a rat model of vasospastic angina and reduces the mean arterial pressure in anesthetized rats. Monatepil also enhances low-density lipoprotein (LDL) receptor activity in human skin fibroblasts. Monatepil can be used in research related to hypertension, atherosclerosis, hyperlipidemia and vasospastic angina.
For research use only. We do not sell to patients.
- CAS No.: 103377-41-9
- Formula: C28H30FN3OS
- Molecular Weight:475.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
α1-adrenergic receptor |
Calcium Channel |
In Vitro
Monatepil (AJ-2615 free base) enhances LDL receptor activity in human skin fibroblasts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Monatepil (0.3 mg/kg; i.v.) significantly inhibits acetylcholine (16 μg/kg; intracoronary administration)-induced ST-segment elevation in male Jcl:Sprague-Dawley rats; the inhibition rate exceeds 60% at a dose of 1 mg/kg[2].
Monatepil (0.1-1 mg/kg; i.v.) reduces the mean arterial pressure of anesthetized male Std:Wistar rats by 14.0, 40.6, and 50.2 mmHg, respectively; at doses of 0.3 and 1 mg/kg, it also significantly decreases heart rate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Nrc:Donryu rats, 120-190 g; vasopressin (0.2 IU/kg, i.v.)-induced ischemic ST-segment depression[2]
-
Dosage:3 mg/kg; 30 mg/kg
-
Administration:Oral administration (p.o.)
-
Result:Significantly inhibited vasopressin-induced ST-segment depression at 3 mg/kg; significant inhibition remained 7 h after 30 mg/kg.
-
Animal Model:Male Jcl:Sprague-Dawley rats, ~500 g; methacholine (16 μg/kg, intracoronary arterial administration)-induced ST-segment elevation[2]
-
Dosage:0.3 mg/kg; 1 mg/kg
-
Administration:Intravenous administration (i.v.)
-
Result:Significantly inhibited ST-segment elevation at 0.3 mg/kg and produced >60% inhibition at 1 mg/kg.
Chemical Information
-
CAS No. 103377-41-9
-
Molecular Weight 475.63
-
Formula C28H30FN3OS
-
SMILES
O=C(NC1C=2C=CC=CC2SCC=3C=CC=CC31)CCCN4CCN(C5=CC=C(F)C=C5)CC4
-
Synonyms
AJ-2615 free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)